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Arene ruthenium complexes as anticancer agents†
Georg Su¨ss-Fink
Neutral or cationic arene ruthenium complexes providing both hydrophilic as well as hydrophobic properties due to the robustness of
the ruthenium–arene unit hold a high potential for the development of metal-based anticancer drugs. Mononuclear arene ruthenium
complexes containing P- or N-donor ligands or N,N-, N,O- or O,O-chelating ligands, dinuclear arene ruthenium systems with
adjustable organic linkers, trinuclear arene ruthenium clusters containing an oxo cap, tetranuclear arene ruthenium porphyrin
derivatives that are photoactive, as well as hexanuclear ruthenium cages that are either empty or ﬁlled with other molecules have been
shown to be active against a variety of cancer cells.
Introduction
Cancer is the second leading cause of death in economically devel-
oped countries and the third leading cause of death in developing
countries.1 Statistically, one in eight Europeanswill develop cancer
during his or her lifetime.2 Although the estimated incidence rates
show rising trends for both sexes, the age-standardized cancer
mortality rate has been falling continuously among women since
1970 and among men since 1985.3 The increase of the survival
rates is due to better cancer treatment, in particular thanks
to the introduction of efﬁcient anticancer drugs which largely
contributed to this improvement.
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Metal-based cancer chemotherapy
Platinum-baseddrugs havebeen in clinical use for cancer treatment
for more than 30 years.4 The landmark discovery of the antitu-
moural properties of cis-diamminedichloroplatinum(II) (cisplatin)
by Rosenberg in 1965 heralded a new area of anticancer research
based on metallopharmaceuticals.5 To date, cisplatin and its
analogues (Fig. 1) are some of themost effective chemotherapeutic
agents in clinical use.6 The square-planar Pt(II) drugs are activated
by slow hydrolysis of the anionic ligands,7 the corresponding
cationic aqua complexes thus formed act by binding to DNA.8
The current understanding of the structure–activity relationships
and the state of the art in targeted chemotherapy with platinum-
based drugs has been reviewed recently by Reedijk.9 The evolution
of platinum-based anticancer agents is a beautiful example of
how it was possible to turn a serendipitous discovery into
pharmaceuticals. However, platinum-based drugs are not without
problems: Their high toxicity and incidence of drug resistance
remain the main challenges in their clinical application.10,11
In the search for anticancer agents containing metals other than
platinum (thus overturning the platinum paradigm), ruthenium
compounds turned out to be the most promising ones.12 The
ligand exchange kinetics of metal complexes in aqueous solution,
which seem to be crucial for the anticancer activity and which
vary for the different metal cations by as much as fourteen orders
of magnitude (rates from 10-6 to 10+8 s-1), are very similar for
platinum(II) and ruthenium(II) complexes; in both cases the ligand
exchange processes are quite slow and may take hours (rates
10-3 to 10-2 s-1).13 Ruthenium has therefore been considered to
be an attractive alternative to platinum, in particular since many
ruthenium compounds are not very toxic and some ruthenium
compounds have been shown to be quite selective for cancer
cells.14,15 This is believed to be due to the ability of ruthenium
to mimic iron in binding to biomolecules. As cancer cells over-
express transferrin receptors to satisfy their increased demand
for iron, ruthenium-based drugs (containing the iron homologue
ruthenium) may be delivered more efﬁciently to cancer cells.16,17
Ruthenium compounds with anticancer properties
The ﬁrst ruthenium compounds to be studied for cancer activ-
ity were chloro-ammine complexes: Durig et al. had observed
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Fig. 1 Platinum(II) complexes approved worldwide for clinical use in cancer treatment.
in 1976 that the ruthenium(III) complex fac-Ru(NH3)3Cl3 in-
duces ﬁlamentous growth of E. coli cells, at the same con-
centration as the required concentration of cisplatin for the
same effect.18 In 1980, this complex as well as the related
ruthenium(II) complex cis-Ru(NH3)4Cl2 were evaluated for their
anticancer properties by Clarke.19 However, although active,
these compounds were not soluble enough for pharmaceutical
use.20 In the following years, a large number of Ru(II) and
Ru(III) compounds were studied for their cytotoxic properties,
in particular polypyridyl complexes such as cis-Ru(N,N-bipy)2Cl2
and mer-Ru(N,N,N-terpy)Cl3 (bipy = 2,2¢-bipyridine, terpy =
2,2¢:6¢2¢¢-terpyridine),21,22 aminocarboxylato complexes such as
Ru(N,N,O,O-pdta)Cl2 or [Ru(N,N,O,O,O-edta)Cl]- (pdta = 1,2-
propylenediaminetetraacetato, edta = ethylenediaminetetraac-
etato) as potassium salt,23,24 dimethylsulfoxide complexes such as
cis- and trans-Ru(S-dmso)4Cl2 (dmso = dimethylsulfoxide),25-27
and arylazopyrdine complexes such as Ru(N,N,N,N-azpy)2Cl2
(azpy = 2-phenylazopyridine).28,29 Since Ru(II) coordinates more
rapidly to biomolecules,20 it has been suggested that Ru(III) is
reduced in vitro to Ru(II).30 This is possible, because cells contain
reducing agents such as glutathione, and tumour cells are often
hypoxic (poor in O2) and more acidic than normal tissue. This
activation mechanism proposed by Clarke has become known as
the “activation by reduction” hypothesis.31
The ﬁrst real breakthrough in the area of classical ruthe-
nium complexes was the introduction of imidazole and in-
dazole ligands by Keppler: the isoelectronic ruthenium(III)
compounds [imiH]trans-[Ru(N-imi)2Cl4] and [indH]trans-[Ru(N-
ind)2Cl4] (imi = imidazole, ind = indazole) were active against
a number of tumour models, in particular against platinum-
resistant colorectal autochthonous tumours.32 Alessio and Sava
reported the imidazole-dimethylsulfoxide ruthenium(III) complex
trans-[Ru(N-imi)(S-dmso)Cl4]- to be speciﬁcally active against
solid metastasizing tumours in mice.33 After extensive preclinical
tests, the compounds [indH]trans-[Ru(N-ind)2Cl4] (KP1019) and
[imiH]trans-[Ru(N-imi)(S-dmso)Cl4] (NAMI-A) (see Fig. 2) went
into clinical trials.4 In accordance with the “activation by reduc-
tion” hypothesis,31 NAMI-AR, obtained by reduction ofNAMI-A
with ascorbic acid prior to administration, was found to be even
more efﬁcient than NAMI-A itself against metastasis growth.34
Arene ruthenium complexes with antitumoural and antimetastatic
properties
Organometallic compounds are generally considered to be toxic
and unstable, undergoing decomposition when exposed to air and
water. While this statement is true for many organometallics,
generalisations of this type are misleading: there are an in-
creasing number of stable, water-soluble organometallic com-
plexes, and aqueous-phase organometallic chemistry is a thriving
subject for industrial catalysis,35,36 as well as for biologically
related topics,37 thus overcoming old teaching paradigms.38 The
term “bioorganometallic chemistry” was introduced in 1985 by
Jaouen,39 stimulating also the search for organometallic anticancer
drugs.
The ﬁeld of antitumoural and antimetastatic arene ruthenium
complexes was pioneered by Dyson and by Sadler,40,41 after
the notion of using arene ruthenium compounds as anticancer
agents had ﬁrst been introduced by Tocher et al. in 1992, who
had observed a cytotoxicity enhancement by coordinating the
Fig. 2 Ruthenium(III) complexes in clinical trials for cancer treatment.
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Fig. 3 Prototype anticancer arene ruthenium complexes reported by Dyson and by Sadler.
anticancer agent metronidazole [1-b-(hydroxyethyl)-2-methyl-5-
nitro-imidazole] to a benzene ruthenium dichloro fragment.42 Ini-
tially, the prototype arene ruthenium(II) complexes evaluated for
anticancer properties in 2001were (h6-p-MeC6H4Pri)Ru(P-pta)Cl2
(pta = 1,3,5-triaza-7-phospha-tricyclo-[3.3.1.1]decane), termed
RAPTA-C, fromDyson’s laboratory,43 and [(h6-C6H5Ph)Ru(N,N-
en)Cl]+ (en = 1,2-ethylenediamine) as hexaﬂuorophosphate salt
as well as some analogues from Sadler’s laboratory (Fig. 3).44
Although RAPTA-C exhibits only a low activity in vitro, it is
very active in vivo, where it inhibits lung metastases in CBA
mice; like NAMI-A, RAPTA-C is also an antimetastatic agent.40
The underlying design of this type of anticancer agents and the
understanding of their mode of action are summarized in some
excellent review articles.6,40,41,45,46
Recent developments with arene ruthenium complexes
Apart from a supposed low general toxicity and a supposed
high selectivity of ruthenium compounds for cancer cells,14,15
the main reasons for the ﬂourishing design of arene-ruthenium-
based anticancer drugs are the amphiphilic properties of the
arene ruthenium unit, provided by the hydrophobic arene ligand
counterbalanced by the hydrophilicmetal centre, and the synthetic
diversity of the arene ligand, which is an excellent scaffold for the
coupling of organic segments for targeted chemotherapy.40
Another important feature is the hydrolysis of Ru–X bonds
to give ruthenium-aqua species (aquation), while the arene–
ruthenium bond is robust. The corresponding aqua complex will
exist over a range of pH, but for pH > pKa the hydroxo complex
formed by deprotonation will be predominant. As hydroxide is a
less labile ligand than water, it will not so easily be displaced by
biomolecule targets. Aquation of the chloro complexes might be
suppressed extracellularly by high chloride concentrations (0.1M)
but becomes possible after the complex enters the cell due to lower
Cl- concentrations (4–25 mM) found intracellularly.41
Mononuclear arene ruthenium complexes containing P- or
N-donor ligands
The inﬂuence of structural variations on the anticancer activity of
RAPTA-C was studied in detail by Dyson (Fig. 4): Variation of
the arene ligand in the prototype complex (h6-p-MeC6H4Pri)Ru(P-
pta)Cl2 (1) revealed that both the para-cymene derivative 1
(RAPTA-C) and the benzene derivative (h6-C6H6)Ru(P-pta)Cl2
(2) (RAPTA-B) inhibit metastasis growth in addition to possess-
ing low general toxicity.47 The toluene and hexamethylbenzene
derivatives (h6-C6H5Me)Ru(P-pta)Cl2 (3) (RAPTA-T) and (h6-
C6Me6)Ru(P-pta)Cl2 (4) (RAPTA-H) are slightly more cytotoxic.6
Variation of the anionic ligands led to the bromo, iodo and isothio-
cyanato analogues 5–7, all these complexes (Fig. 4) are cytotoxic
and show antimicrobial but no antiviral activity.48 Replacement
of the two chloro ligands in 1 by bridging anionic ligands
gave the oxalato complex (h6-p-MeC6H4Pri)Ru(P-pta)(O,O-C2O4)
(8),49 and the diketonato complexes [(h6-p-MeC6H4Pri)Ru(P-
pta)(O,O-R2acac)]+ (9–11),50 which resist hydrolysis without this
phenomenon having a great impact on the cytotoxicity.
On the other hand, the water-soluble phosphine ligand pta
seems to play a signiﬁcant part in determining the selectivity for
cancer cells. When pta was replaced by the N-methylated pta-
Me+, the selectivity was lost, complex [(h6-p-MeC6H4Pri)Ru(P-
pta-Me)Cl2]+ (12) being equally cytotoxic in both cancerous and
non-tumourigenic cell lines.47 However, replacement of pta by
ptn (3,7-dimethyl-7-phospha-1,3,5-triazabicyclo[3.3.1]nonane), a
P,N-four-electron donor, to give [(h6-p-MeC6H4Pri)Ru(P,N-
ptn)Cl]+ (13) (Fig. 4) had little inﬂuence on the cytotoxicity
with respect to that of 1.51 In contrast to the expectations,
the introduction of hydrogen-bonding substituents in the arene
ring, such as in [(h6-C6H5CH2CH2NH3)Ru(P-pta)Cl2]+ (14),
does not enhance the cytotoxicity but actually has the reverse
effect.52
The question of whether the aromatic fragment in the ruthe-
nium complexes of the RAPTA type (piano-stool geometry) is
essential for the anticancer activity was addressed by Alessio,
who synthesized the 1,4,7-trithiacyclononane ([9]aneS3) complex
([9]aneS3)Ru(P-pta)Cl2 (15), which is isoelectronic to 1 without
being organometallic (Fig. 5), and derivatives thereof. The results
clearly suggest that the aromatic ligand is not an essential feature
for the cytotoxicity and that it can be effectively replaced by
another face-capping six-electron ligand with low sterical demand
and hydrophobic properties.53,54
Replacing the arene ligand with another p-ligand, the ﬁve-
electron donor cyclopentadienyl system showed a remarkable
cytotoxicity dependence on the substituents at the ring: While
the complex (h5-C5H5)Ru(P-pta)2Cl (16) is inactive on human
ovarian cancer cell lines, thewater-soluble but lipophilic complexes
(h5-C5HCH2ButBut2OR)Ru(P-pta)2Cl (17: R = Me, 18: R = Et)
are more active than the RAPTA compounds, the cytotoxicity
being comparable to that of cisplatin; this has been explained by
an increased uptake due to the high lipophilicity.55 Complex 19
containing a 3-hydroxy-2-pyridone ligand (Fig. 5), which exists in
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Fig. 4 Structural variations of the ligands in the lead compound RAPTA-C.
Fig. 5 RAPTA analogues showing similar or enhanced cytotoxicities.
aqueous solution as a mononuclear complex cation (pH< 7) or as
a neutral trinuclear complex, in which the deprotonated pyridone
nitrogen atom replaces the aqua ligand of a neighbour ruthenium
atom (pH > 8.5), is slightly less active and also less selective
than 1 towards human ovarian cancer cells; it was not possible
to ascertain whether or not a pH-dependent process involving
a structural change takes place.56 Finally, arene osmium and
pentamethylcyclopentadienyl rhodium RAPTA analogues such
as 20 (Fig. 5) have been shown to have very similar cytotoxicity
proﬁles to those of 1, suggesting that the anticancer potential of
neighbouring elements to ruthenium should not be overlooked.57
Since these ﬁndings were somewhat controversial, and as the
modes of action of RAPTA-type anticancer compounds were
largely unexplored,16 somemechanistic andmodelling studies have
been undertaken. The aquation of RAPTA-C (1) in water was
studied by UV-Vis and NMR spectrometry: during the hydrolysis
process in 1 mM solution, the percentage of 1 decreases to 18%,
the cationic aqua-chloro complex 1a is predominant at 70%,
while the cationic aqua-hydroxo complex 1b is present at 12%,
the equilibrium being reached after 20 minutes (Scheme 1).58
Aquation seems to be the activating step in the cytotoxicity of
1, hydrolysis is suppressed in the blood plasma where the chloride
concentration is about 100 mM, but occurs once the compound
penetrates the cell cytoplasma where chloride concentrations are
much lower. Then the labile aqua ligand is prone to substitution
by biomolecules.40 The hydrolysis-resistant complexes 8–11, which
are also cytotoxic, are presumably activatedby anothermechanism
which may involve ring slippage of the arene.49,50
It is generally believed that the target of arene-ruthenium-based
anticancer drugs within the cancer cell is DNAorRNA, but serum
proteins may also be targets.40 Early on, it had been observed that
RAPTA-C (1) induces pH-dependent DNA damage.43 Binding
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Scheme 1 Hydrolysis of 1 (RAPTA-C) in pure water at 1 or 2 micromolar concentration.
studies using calf thymus DNA further suggested that 1 causes
denaturation by double-helix stabilisation upon binding.47 Indeed,
1 showed pH-dependent reactivity towards the DNA model com-
pound 2¢-deoxiguanosione-5¢-monophosphate (dGuaRP) with an
up to tenfold higher amount of ruthenium in the dGuaRP-
bound form at pH = 6 (typical for cancer cells) as compared
to pH = 7.4 (typical for healthy cells),59 and 1 was found to
react with purine bases as DNA model compounds, in particular
with guanine.60 However, in the reaction with the single-strand 14-
mer oligonucleotide d(ATACATGGTACATA) it was not possible
to identify preferential binding sites; the binding occurs with
loss of the chloro ligand and – surprisingly – also the arene
ligand, while the pta ligand remains coordinated.61 On the basis
of DFT calculations, it was suggested that the interaction with
the arene-free ruthenium fragment is based on multiple N-donor
bonds, possible only in RNA, therefore RNA and serum proteins
appear to be the main intracellular targets.6,61 Sadler isolated
the arene ruthenium enzyme complex (h6-p-MeC6H4Pri)Ru(N-
lysozyme)Cl2 from the reaction of [(h6-p-MeC6H4Pri)Ru(H2O)Cl2
with the single-chain protein lysozyme (containing 129 amino acid
residues); this enzyme complex could be structurally characterized
and showed the ruthenium to be coordinated to the N3 atom of
the histidine-15 unit of lysozyme.62
An ESI-MS characterisation of protein adducts showed re-
action of 1 with horse heart cytochrome-c and with hen egg
white lysozyme revealed stable metalloadducts containing [(h6-
p-MeC6H4Pri)Ru(P-pta)] and [(h6-p-MeC6H4Pri)Ru] fragments,
preferentially bound to surface histidines.63 Recently, it was found
that RAPTA-C (1) as well as its derivates and analogues inhibit
two speciﬁc enzymes that are believed to be targets in cancer
chemotherapy: RAPTA compounds are potent inhibitors of
cathepsin B and weak inhibitors of thioredoxin reductase.64 It
has also been shown that 1 induces apoptosis and slows down cell
division in cancer cells.65
The RAPTA moiety was tethered to human serum albumin
(HSA), known to accumulate in tumours by modiﬁcation of HAS
with hydrazine groups and by subsequent hydrazone formation
with the RAPTA-aldehyde derivative 21 (Fig. 6), causing a
twentyfold increase of the cytoxicity with respect to 1.66 On the
other hand, replacement of pta by 3,5,6-bicyclophosphite-a-D-
glucofuranoside ligands leads to RAPTA analogues such as 22,
which is more cytotoxic than RAPTA compounds such as 1, due
to its increased lipophilicity.67
Beyond the conventional approach of drug discovery, relying
largely on screening for biological activity, deriving structure–
activity relationships and testing for improved drug efﬁciency,
targeted drug design becomes more and more important: the next
generation RAPTA derivatives and analogues were designed to
have multiple modes of activity, functionalized to achieve speciﬁc
outcomes.6
The glutathione transferase (GST) P1-1, a cytosolic detoxiﬁ-
cation enzyme, is often found in solid tumours, and its overex-
pression after exposure to anticancer agents has been reported.68
Ethacrynic acid is an effective GST inhibitor, particularly with
GST P1-1, where it binds competitively to the H-site.69 As proof
of concept, the RAPTA derivatives 23 and 24 (Fig. 7), in which the
Fig. 6 RAPTA derivatives and analogues for drug delivery studies.
5
Fig. 7 Ethacrynic acid RAPTA derivatives as glutathione transferase inhibitors.
arene ligand is coupled to ethacrynic acid either by an amide or
by an ester bond, have been synthesized and shown to be excellent
GST P1-1 inhibitors.70
Apart from the complexes of the RAPTA family containing
the water-soluble pta as P-donor ligand, mononuclear arene
ruthenium complexes containing N-donor ligands have also
been reported as anticancer agents, in particular complexes
containing imidazole ligands. Inspired by the work of Keppler
and Sava: the compounds [indH]trans-[Ru(N-ind)2Cl4] (KP1019)
and [imiH]trans-[Ru(N-imi)(S-dmso)Cl4] (NAMI-A) (see Fig. 2),
which are already in clinical trials,4 contain imidazole or indazole
ligands. The low systemic toxicity of KP1019 is attributed, at least
in part, to transferrin-mediated drug transport,71 with KP1019
binding strongly to transferrin in the iron-binding pocket.72 Its
imidazolium analogue, which binds more weakly to transferrin is
taken up less effectively by the cells.73
In an attempt to synergistically combine the arene ruthenium
piano-stool characteristics of the RAPTA complexes with the
imidazole ligand properties of the NAMI-A system, Dyson
synthesized a whole series of arene imidazole complexes such
as (h6-p-MeC6H4Pri)Ru(N-imiR)Cl2 (imiR = N-methylimidazole
25, N-benzoylimidazole 26), [(h6-p-MeC6H4Pri)Ru(N-imiR)2Cl]+
(imiR = N-methylimidazole 27, N-vinylimidazole 28) (Fig. 8) and
[(h6-p-MeC6H4Pri)Ru(N-imiR)3]2+ (imiR = N-methylimidazole
29), which showed essentially the same order of cytotoxicity as
the RAPTA compounds toward cancer cells.74
Imidazole ligands also allow the introduction of substituents
that endow biological function to the arene ruthenium unit.
Thus, phenoxazine- and anthracene-based multidrug resistance
modulator substituents have been introduced via an imida-
zole linker in (h6-p-MeC6H4Pri)Ru(N-imiR)Cl2 (imiR = N-
phenoxbenzimidazole 30, N-anthramimidazole 31) in an effort
to develop antitumour drugs that overcome multidrug resistance
mechanisms; for the most powerful P-glycoprotein inhibitor 31
(Fig. 8), the inhibition of DNA synthesis is a possible mechanism
of the cytotoxic action.75
A family of arene ruthenium complexes containing an amide of
the GST inhibitor ethacrynic acid in an imidazole ligand was also
synthesized by Dyson. Apart from the dichloro derivative (h6-
p-MeC6H4Pri)Ru(N-L)Cl2 (L = ethacrynic N-imidazole propyl
amide, 32) (Fig. 8), the oxalato and 1,1-cyclobutanedicarboxylato
complexes (h6-p-MeC6H4Pri)Ru(N-L)(O,O-C2O4) (33) and (h6-
p-MeC6H4Pri)Ru(N-L)(O,O-C6H6O4) (34) have been shown to
inhibit GST P1-1 and its cysteine-modiﬁed mutants and to be
Fig. 8 Cytotoxic imidazole and chloroquine arene ruthenium complexes.
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Fig. 9 Cytotoxic arene ruthenium complexes containing ethylenediamine ligands.
active against human ovarian cancer cell lines.76 The chloroquine
(clq) complex (h6-p-MeC6H4Pri)Ru(N-clq)Cl2 (35) (Fig. 8), re-
cently designed by Sa´nchez-Delgado, not only has antimalarial
properties but also a remarkable anticancer activity in vitro,
especially towards liposarcoma cell lines.77
Mononuclear arene ruthenium complexes with N ,N-, N ,O- or
O,O-chelating ligands
In contrast to the phosphine complexes of the RAPTA family
that have only a low cytotoxicity in vitro but a high metastatic
activity in vivo,47 thus being inactive against primary tumours
but active towards secondary metastasis tumours,16 the cationic
arene ruthenium complexes containing ethylenediamine chelating
ligands reported by Sadler (Fig. 9) show very high cytotoxicities
in vitro as hexaﬂuorophosphate salts, and they are also very active
in vivo.
Thus, [(h6-C6H5Ph)Ru(N,N-en)Cl]+ (36), [(h6-p-MeC6H4Pri)-
Ru(N,N-en)Cl]+ (37) and [(h6-p-MeC6H4Pri)Ru(N,N-en)I]+ (38)
as well as the N,N¢-diethylethylenediamine (enEt2) derivative [(h6-
C6H5Ph)Ru(N,N-enEt2)Cl]+ (39) inhibit the growth of human
ovarian cancer cells (A2780)with IC50 values comparable to that of
carboplatin (6 mM),44 while the more hydrophobic tetrahydroan-
thracene (tha) derivative [(h6-tha)Ru(N,N-en)Cl]+ (40) is equipo-
tent with cisplatin (0.6 mM).78 Interestingly, arene ruthenium
complexes containing two monodentate N-donor ligands instead
of a chelating diamine ligand, such as [(h6-p-MeC6H4Pri)Ru(N-
NCMe)2Cl]+ (41) are almost inactive toward the A2780 cell line,
and structure–activity relationships showed that the most active
complexes contain a stable bidentate N,N-donor ligand, a more
hydrophobic arene ligand, and a halide as exchangeable ligand.44
It was also shown that in water [(h6-p-MeC6H4Pri)Ru(N,N-
en)Cl]+ (37) undergoes rapid aquation to give [(h6-p-
MeC6H4Pri)Ru(N,N-en)(H2O)]2+ (42) and [(h6-p-MeC6H4Pri)-
Ru(N,N-en)(OH)]+ (42a); this hydrolysis can be suppressed in
0.1 M NaCl (Scheme 2).44
The aquation kinetics of the biphenyl, tetrahydroanthracene
and dihydroanthracene complexes [(h6-C6H5Ph)Ru(N,N-en)Cl]+
(36), [(h6-tha)Ru(N,N-en)Cl]+ (40) and [(h6-dha)Ru(N,N-en)Cl]+
(43) have also been studied: The hydrolysis is essentially indepen-
dent of ionic strength and increases with the size of the arene,
the aquation reaction is about twenty times faster than that of
cisplatin, the pKa values of the corresponding aqua complexes (h6-
C6H5Ph)Ru(N,N-en)(H2O)]2+, [(h6-tha)Ru(N,N-en)(H2O)]2+ and
Scheme 2 Hydrolysis of 37 to give 42 and 42a in water at a 10 micromolar concentration.
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[(h6-dha)Ru(N,N-en)(H2O)]2+ being 7.71, 7.89 and 8.01, respec-
tively. The reverse reactions (anation) are also very rapid on
addition of 100mMNaCl (comparable to blood plasma), reaching
equilibrium after 100 to 1600 s.79
The interaction with DNA model compounds has been exten-
sively investigatedbySadler: in contrast toRAPTA-C,where itwas
not possible to identify preferential DNA binding sites with the
single-strand 14-mer oligonucleotide d(ATACATGGTACATA),61
the analogous reaction of 37 shows the intermediary aqua
complex 42 to ruthenate DNA speciﬁcally at guanine positions
to give two G7- or G8-monoruthenated derivatives as well as a
G7,G8-diruthenated DNA species.44 The self-complementary 6-
mer oligonucleotide d(CGGCCG), which exists single-stranded
[ss-d(CGGCCG)] or as a duplex [d(CGGCCG)2], reveals the
effect of base-pairing on the guanine ruthenation: whereas in
ss-d(CGGCCG) all three guanine positions are ruthenated with
arene ruthenium ethylenediamine units (with excess ruthenium
only the triruthenated product being observed), in the duplex
d(CGGCCG)2 only G3 and G6 are ruthenated, but not G2. By
comparing the para-cymene derivative 32, which cannot act as
a DNA intercalator, and the biphenyl derivative 36, which is
a potential DNA intercalator, indeed intercalation of the non-
coordinated phenyl ring of 36 between G3 and C4 or G6 and C5 is
observed in the mono- and diruthenated duplexes, together with
weakening of the (G)O ◊ ◊ ◊H(en) hydrogen bonding.80
In a comparative study with various DNA bases, it was
established that arene ruthenium ethylenediamine units bind
preferentially to N7 of guanine. NMR observation of the species
produced after 24 hours by reacting complex 36 with guanosine,
inosine, thymidine, cytidine and adenosine revealed the base
selectivity order G(N7) > I(N7) > I(N1) > T(N3) > C(N3) >
A(N7) > A(N1) > G(N1), which can be rationalized in terms of
hydrogen bonding attraction or repulsion.81
In order to gain insight into the interaction factors including
covalent ruthenium–guanine bonding, hydrophobic interactions
of the arene ligand and NH hydrogen bonding of the ethylene-
diamine ligand, complexes [(h6-C6H5Ph)Ru(N,N-en)Cl]+ (36),
[(h6-tha)Ru(N,N-en)Cl]+ (40) and [(h6-dha)Ru(N,N-en)Cl]+ (43)
were reacted with the guanine derivatives 9-ethylguanine (guaEt),
guanosine (guaRi) and guanosine 5¢-monophosphate (guaRP),
see Scheme 3; the products were studied in the solid state by X-
ray crystallography and in solution by 2D NMR methods.82 In
all cases, the arene ruthenium ethylenediamine unit was found to
coordinate to the N7 atom of the guanine derivative. In the crystal
structure of [(h6-C6H5Ph)Ru(N,N-en)(N7-guaEt)][PF6]2·MeOH
(cation 44), there is intermolecular stacking between the pendant
phenyl ring and the six-membered purine ring, while strong p–
p arene–nucleobase stacking is present in the crystal structures
of [(h6-tha)Ru(N,N-en)(N7-guaEt)][PF6]2·MeOH (cation 45) and
[(h6-dha)Ru(N,N-en)(N7-guaEt)][PF6]2·2MeOH (cation 46); in
[(h6-C6H5Ph)Ru(N,N-en)(N7-guaRi)][PF6]2·3.75H2O (cation 47)
intramolecular stacking between the pendant phenyl ring and
the purine ﬁve-membered ring is observed. In all these structures
strong stereospeciﬁc hydrogen bonding is present between an en
NH group and the C6 carbonyl group of the guanine system,
suggesting that simultaneous covalent coordination, intercala-
tion and stereospeciﬁc hydrogen bonding are involved in the
DNA recognition behaviour of arene ruthenium ethylenediamine
complexes.82
Modiﬁcation of natural DNA in a cell-free medium by the
arene ruthenium ethylenediamine complexes 36, 37, 40 and 43,
as well as the benzene parent complex [(h6-C6H6)Ru(N,N-en)Cl]+
(48), have been studied by atomic absorption, melting behaviour,
transcription mapping, circular and linear dichroism, plasmid
unwinding, competitive ethidium displacement and differential
pulse polarography. The results indicate that the arene ruthenium
ethylenediamine units bind preferentially to guanine residues
in double-helical DNA. The data are consistent with DNA
binding of complexes containing biphenyl, dihydroanthracene or
tetrahydridoanthracene ligands that involves combined covalent
Ru–N (guanine N7) coordination and non-covalent hydrophobic
interactions between the arene ligand and DNA, which may
include arene intercalation andminor groove binding. In contrast,
the single arene rings in the para-cymene and benzene complexes
cannot interact with double-helical DNA by intercalation.83
Although arene ruthenium ethylenediamine complexes seem
to target the DNA of the cancer cells, reactions with other
biologically relevant molecules have been studied, in particular
with amino acids and peptides, in order to see if the metal complex
undergoes chemical transformations in the cell culture medium,
the blood plasma, the cell membrane or in the cytoplasma before it
reaches theDNA target, or if serumproteinsmay even be targets of
these anticancer agents. The most important biomolecules studied
in this respect by Sadler include the sulfur-containing amino acids
L-cysteine and L-methionine, the imidazole-containing amino
acid L-histidine, the tripeptide glutathione, an abundant intra-
cellular thiol responsible for the detoxiﬁcation of heavy transition
metal ions, and the electron-transfer protein cytochrome-c.
Scheme 3 Coordination of arene ruthenium ethylenediamine fragments to guanine derivatives (hydrogen bonding not shown).
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From the reaction of the biphenyl derivative 36 with L-cysteine
(cysH2), six products have been identiﬁed by HPLC, LC-ESI-MS
and NMR techniques. After 48 hours, only 50% of 36 had
reacted, and the ﬁnal products were the dinuclear complexes [(h6-
C6H5Ph)Ru(H2O)(mN,S-cys)Ru(h6-C6H5Ph)(N,N-en)]2+ (48) and
(h6-C6H5Ph)Ru(H2O)(mN,S-cys)(mN,S,O-cys)Ru(h6-C6H5Ph)
(49). From the analogous reactionwithL-methionine (metH), only
the sulfur-bound complex [(h6-C6H5Ph)Ru(N,N-en)(S-metH)]2+
(50) was detected, with only 27% completion after 48 hours.84
The reaction of 36 with L-histidine (hisH2) to give the isomeric
products [(h6-C6H5Ph)Ru(N,N-en)(N1-hisH2)]2+ (51) and [(h6-
C6H5Ph)Ru(N,N-en)(N3-hisH2)]2+ (52) was found to be slow, too;
after 24 hours the equilibriumwas reachedwith 22% completion.85
When the biphenyl complex 36 was reacted with glutathione
(glSH), a peptide formed from the three amino acids L-glutamic
acid, L-cysteine and glycine under physiologically relevant condi-
tions (millimolar concentrations), the sulfur-bound glutathionato
complex [(h6-C6H5Ph)Ru(N,N-en)(S-glS)]+ (53) and its oxidation
product [(h6-C6H5Ph)Ru(N,N-en)(S-glSO)]+ (54) containing a
sulfenato function were formed. When the reaction was done in
an argon atmosphere, only 53 was detected, proving that 54 arises
from the reaction with molecular oxygen from air.86 A sulfenato
complex of this type, [(h6-p-MeC6H4Pri)Ru(N,N-en)(S-S(O)Pri)]+
(55), was isolated from the reaction of the corresponding thio-
lato complex [(h6-p-MeC6H4Pri)Ru(N,N-en)(S-SPri)]+ (56) with
hydrogen peroxide and structurally characterized as the iodide
salt.87 Complex 36 was also found to react with the electron
transfer protein cytochrome-c to give twomonoruthenated protein
adducts thought to contain a ruthenium bound to the N-terminus
or to a carboxylate.85
In the competitive reaction of 36 with glutathione and with
guanosine-3¢,5¢-cyclic monophosphate (cGMP) under physiologi-
cal conditions (pH 7, 310 K, 20 mM 36, 250 equivalents glSH, 25
equivalents cGMP, 10 mM phosphate buffer, 22 mM NaCl), the
major product was [(h6-C6H5Ph)Ru(N,N-en)(N7-cGMP)]2+ (57),
but 53 and 54 were also observed.86 The competitive reaction
of 36 (0.2 mM) with cytochrome-c (0.1 mM) and with the 14-
mer oligonucleotide d(ATACATGGTACATA) (0.1 mM) showed
that 90% of the oligonucleotide had reacted to give mono-
or diruthenated adducts.85 These results clearly suggest that in
the cells, DNA (or RNA) are the favoured targets of arene
ruthenium ethylenediamine complexes.41 Radiolabelling studies
with the hexaﬂuorophosphate salt of the ﬂuorene (ﬂu) complex
[(h6-ﬂu)Ru(N,N-en)Cl]+ (58) containing the radionucleide 106Ru
showed that 106Ru is well distributed throughout the rat tissues 15
minutes after intravenous injection of a saline solution at a dose
of 10 mg per kg to a living rat, the highest level being found in
liver and kidney.88
In an extension to otherN,N-chelating ligands, Sadler observed
a loss of cytotoxicity, when in complexes of the type [(h6-
arene)Ru(N,N-en)Cl]+ the s-donor chelating ligand ethylenedi-
amine was replaced by 2,2¢-bipyridine (bipy) and its derivatives,
which are also strong p-acceptors. Thus, [(h6-C6H5Ph)Ru(N,N-
bipy)Cl]+ (59) is almost inactive toward human ovarian and lung
cancer cell lines; it was shown that initial aquation is followed by
partial arene loss.89 Incorporation of methyl, hydroxymethyl or
methylester groups in the 4,4¢ positions of the bipyridine ligand
did not restore the activity. However, complexes containing 2,2¢-
bipyridine-3,3¢-diol [bipy(OH)2] as chelating ligand showed a dra-
matic increase in the anticancer activity; in aqueous solution only
neutral complexes with a deprotonated chelating bipyOHO ligand
are present over a pH range from 2 to 10, such as [(h6-tha)Ru(N,N-
bipyOHO)Cl]+ (60), see Fig. 10. Complex 60 also strongly binds
to 9-ethylguanine; the X-ray crystal structure analysis of [(h6-
C6H5Ph)Ru(N,N-bipyOHO)(guaEt)][PF6] shows intramolecular
CH–p interactions between the arene ligand and the bipy system,
and DFT calculations suggest that their interactions are more
stable than p–p interactions between the arene ligand and the
guanine system.90
Arene ruthenium complexes containing N,O- and O,O-
chelating ligands have also been studied by Sadler, in partic-
ular the complexes (h6-p-MeC6H4Pri)Ru(N,O-gly)Cl (61), (h6-
p-MeC6H4Pri)Ru(N,O-ala)Cl (62), (h6-C6H5Ph)Ru(N,O-pro)Cl
(63), derived from the amino acids glycine (glyH), L-alanine
(alaH), and proline (proH), the oxinato complex [(h6-p-
MeC6H4Pri)Ru(N,O-oxi)Cl]+ (64) (oxiH = 8-hydroyquinoline),
or complexes of the type (h6-p-MeC6H4Pri)Ru(O,O-acacMe2)Cl
(65) (HacacMe2 = 1,3-dimethylacetylacetone), see Fig. 10. They
are also moderately cytotoxic and were shown to coordinate to
guanine (N7 binding).89
Tethered arene ruthenium amine complexes of the type [h6:h1-
C6H5(CH2)3NH2]RuCl2 (66) (Fig. 11) hydrolyze rapidly in aqueous
solution to give the cationic monoaqua monochloro species but
show almost no activity toward human ovarian cancer cells.
The dinitrato analogue [h6:h1-C6H5(CH2)3NH2]Ru(O-NO3)2 (67)
readily ruthenates calf thymus DNA but fails to produce stop
sites on pSP73KP plasmid DNA during DNA transcription by an
RNA polymerase, suggesting only monofunctional DNA adducts
to be formed; this may explain the low cytotoxicities of this type
of complex.91
Given their inherent catalytic potential, organometallic
molecules may lead to potentially newmechanisms of drug action,
as compared to purely organic molecules. Sadler showed that
the presence of both an iodo ligand and a para-substituted
phenylazopyridine chelating ligand in the complexes [(h6-
C6H5Ph)Ru(N,N-azpyR)I]+ (R = NMe2 68, R = OH 69) (Fig. 11)
and [(h6-p-MeC6H4Pri)Ru(N,N-azpyR)Cl]+ (R = NMe2 70, R =
OH 71) confers a remarkable inertness toward ligand substitution
(aquation) to these systems. Surprisingly, despite this inertness,
these complexes have been found to be highly cytotoxic toward
human ovarian (A2780) and human lung (A549) cancer cells (IC50
2–6 mM). Fluorescence trapping experiments suggested that the
cytotoxicity arises from an increase in reactive oxygen species
(ROS) such as the superoxide radical anion, the hydroxyl and
hydroperoxyl radicals, hydrogen peroxide and singlet oxygen,
which is due to the depletion of glutathione (glSH), a ROS
scavenger, presumably caused by the oxidative coupling of glSH
to give glutathione disuldide (glS–Sgl) catalyzed by 68–71.92
The paullone-derived ruthenium complexes [(h6-p-
MeC6H4Pri)Ru(N,N-pauR)Cl]+ [R = C6H4OH 72, R =
C5HNMe(CH2OH)OH 73] and their osmium analogues 74
and 75 (Fig. 12), synthesized recently by Keppler in the form
of their chloride salts, have been found to show a very high
antiproliferative activity in three human cancer cell lines, the IC50
values being in the submicromolar concentration range.93
The fact that in this case ruthenium and osmium analogues do
not differ in their biological activity has been interpreted in terms
of a different mechanism to those accepted for arene ruthenium
9
Fig. 10 Cytotoxic arene ruthenium complexes with N,N-, N,O- or O,O-chelating ligands.
Fig. 11 Arene ruthenium complexes with tethered amine or with azopyridine ligands.
Fig. 12 Arene ruthenium and osmium complexes containing paullone-derived N,N-ligands.
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complexes (covalent DNA binding after hydrolysis), either by
non-covalent DNA binding (intercalation) or by interactions with
proteins.93
Multinuclear arene ruthenium complexes and clusters
In platinum chemistry, trinuclear complexes such as [trans,
trans,trans-(NH3)2Pt(Cl)(CH2)6NH2Pt(NH3)2NH2(CH2)6NH2Pt -
(NH3)2(Cl)][NO3]4 (termed BBR3464) were found to show a
higher cytotoxicity than cisplatin in vitro and,94 despite clinical
failure in phase II,95 gave rise to expectations that multinuclearity
could considerably improve the curative activity of anticancer
drugs. This multinuclearity concept was recently transferred to
ruthenium.96
The dinuclear arene ruthenium complexes (h6-p-MeC6H4Pri)-
Ru(O,O-C6H5O2N(CH2 )nNC6H5O2 -OO)Ru(h6 -p-MeC6H4Pri )
(76–81) containing a pyridone-derived linker (Fig. 13) reported
by Hartinger show interesting cytotoxic effects against human
ovarian (A2780) and colon (SW480) cancer cell lines. A pro-
nounced inﬂuence of the spacer length and cytotoxicity was
found (A2780 IC50 25 mM for 77, 30 mM for 79, 1,5 mM for
81, SW480 IC50 62 mM for 77, 26 mM for 79, 0.3 mM for 81),
the cytotoxicity being correlated with lipophilicity and water
solubility.97,98 This is in line with the cytotoxicities we found for
dinuclear ferrocenyl pyridine arene ruthenium complexes [(h6-p-
MeC6H4Pri)RuCl2]2(NC5H4OOCC5H4FeC5H4COOC5H4N) (82)
(Fig. 14) and [(h6-C6Me6)RuCl2]2(NC5H4OOCC5H4FeC5H4COO-
C5H4N) (83).99
Fig. 13 Dinuclear arene ruthenium complexes with pyridone-based
O,O:O,O-bridges.
A detailed structure–activity relationship was established based
on water/octanol partition and hydrolytic stability, showing that
only the most lipophilic long chain (n = 12) complex 81 is
highly active.100 The reactivity of representative complexes towards
proteins and nucleotides was also studied: Complex 77 forms a
1:1 adduct with transferrin, but not with other relevant proteins
like ubiquitin or cytochrome-c, and complexes 79 and 80 react
with guanosine 5¢-monophosphate (guaRP) and with adenosine
5¢-monophosphate (adeRP), but not with other nucleotides; the
reaction of 79 and 80 with calf thymus DNA resulted in a
high degree of ruthenation. These results demonstrate that both
proteins and nucleobases are potential targets for these arene
ruthenium complexes.100
Dinuclear arene ruthenium complexes containing 2,3-bis(2-
pyridyl)pyrazine (dpp) as doubly chelating ligands in the
N,N:N,N-bridge have been synthesized and studied for pho-
toactivation by Sadler in view of their potential for pho-
todynamic therapy: while the benzene and indane deriva-
tives [{(h6-C6H6)RuCl}2(N,N:N,N-dpp)]2+ (84) and [{(h6-
C9H10)RuCl}2(N,N:N,N-dpp)]2+ (85) (Fig. 14) readily undergo
arene loss uponUV irradiation, the para-cymene and hexamethyl-
benzene derivatives [{(h6-p-MeC6H4Pri)RuCl}2(N,N:N,N-dpp)]2+
(86) and [{(h6-C6Me6)RuCl}2(N,N:N,N-dpp)]2+ (87) do not. The
photochemistry of the indane derivative 85was studied in detail. In
water, aquation occurs in the dark; UV or visible light leads to a
dissociation of the indane ligand, visualized by its ﬂuorescence,
and to the formation of strong diruthenium DNA adducts.
These complexes therefore have the potential to combine both
photoinduced cell death and ﬂuorescence imaging of the location
and the efﬁciency of the photoactivation process.101
We found the water-soluble chloride or tetraﬂuoroborate
salts of the cationic trinuclear arene ruthenium clusters [(h6-
C6Me6)2(h6-C6H6)Ru3(m2-H)3(m3-O)]+ (88) and [(h6-C6Me6)(h6-
p-MeC6H4Pri)(h6-C6H6)Ru3(m2-H)3(m3-O)]+ (89) to be cytotoxic
against human ovarian cancer cells with A2780 IC50 values of 9.8
and 9.1mM, respectively,while the tetranuclear cluster cations [(h6-
C6H6)4Ru4(m3-H)4]2+ (90) and [(h6-C6H5Me)4Ru4(m3-H)4]2+ (91),
which contain the same type of ligands and are of comparable size,
do not display signiﬁcant cytotoxicities. This striking difference
between Ru3 and Ru4 cluster cations (Fig. 15), all of which are
Fig. 14 Dinuclear arene ruthenium complexes with nitrogen-containing bridging ligands.
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Fig. 15 Tri- and tetranuclear arene ruthenium cluster cations.
stable in aqueous solution, was explained by supramolecular
interactions with biomolecules possible for the trinuclear clusters
thanks to an open hydrophobic pocket spanned by the three
arene ligands and to the hydrophilic oxo cap prone to form
hydrogen bonds, both ofwhich are not possible for the tetranuclear
clusters.102
Tetranuclear arene ruthenium complexes containing the por-
phyrin scaffold have been designed for photodynamic ther-
apy (PDT) in an effort to combine the photodynamic action
of porphyrin (presumably by singlet oxygen production) with
the cytotoxicity of ruthenium (presumably by DNA denatura-
tion). With 5,10,15,20-tetra(4-pyridyl)porphyrin (4-tpp) as the
central unit, the para-cymene and toluene derivatives [(h6-p-
MeC6H4Pri)RuCl2]4(4-tpp) (92) and [(h6-C6H5Me)RuCl2]4(4-tpp)
(93) (Fig. 16) proved to be very efﬁcient against ME300 and
ME275 melanoma cells: While the cytotoxicities in the dark
are not very high (IC50 > 80 mM), the complexes become very
cytotoxic upon exposure to light (laser 652 nm), a light dose of
5 J/cm2 already causes a phototoxicity of 60–80%, and a light
dose of 30 J/cm2 90–95%. The ruthenation of the porphyrin
system not only increases the solubility of the system (in aqueous
solution aquationof the chloro ligands beingpossible), but also the
selectivity for cancer cells. Fluorescence microscopy revealed that,
while the ruthenated 4-tpp derivatives 92 and 93 are internalized in
ME300 cells, the isoelectronic pentamethylcyclopentadienyl (Cp*)
rhodium derivative [(h5-C5Me5)RhCl2]4(4-tpp) (94) does not enter
the cells under the same conditions (24 hours incubation in the
dark).103
The isomeric 5,10,15,20-tetra(3-pyridyl)porphyrin (3-tpp) para-
cymene and toluene derivatives [(h6-p-MeC6H4Pri)RuCl2]4(3-tpp)
(95) and [(h6-C6H5Me)RuCl2]4(3-tpp) (96) (Fig. 16) turned out
to be even more efﬁcient, very low light doses (less than
0.5 J/cm2) and low concentrations (5 mM) are required to
induce cell death. The reason for higher efﬁciency is presum-
ably a less pronounced aggregation of the complexes in the
cell cytoplasma. Fluorescence microscopy revealed a homo-
geneous distribution in the cytoplasma for the 3-tpp deriva-
tive 96, while for the 4-tpp derivative 93 an accumulation
of red spots (porphyrin ﬂuorescence) in the cytoplasma is
observed.104
Fig. 16 Tetranuclear arene ruthenium complexes containing a porphyrin scaffold for PDT.
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Fig. 17 Tetranuclear arene ruthenium complex cations with rectangular geometry.
Fig. 18 Hexanuclear arene ruthenium complex cations with cage-like geometry.
We also synthesized rectangular tetranuclear arene ruthenium
complex cations incorporating 2,5-dihydroxy-1,4-benzoquinato
(dbq) and dipyridyl linkers, which proved to be active against
human ovarian (A2780) cancer cells, showing a pronounced size
effect: while the smaller rectangles containing bipyridine (bipy)
bridges, [{(h6-p-MeC6H4Pri)Ru}4(N,N-bipy)2(O,O:O,O-dbq)2]4+
(97) and [{(h6-C6Me6)Ru}4(N,N-bipy)2(O,O:O,O-dbq)2]4+ (98)
are only moderately cytotoxic (IC50 66 and 27 mM, respectively),
the larger rectangles containing 1,2-bis(4-pyridyl)ethane (bpe)
bridges, [{(h6-p-MeC6H4Pri)Ru}4(N,N-bpe)2(O,O:O,O-dbq)2]4+
(99) and [{(h6-C6Me6)Ru}4(N,N-bipy)2(O,O:O,O-bpe)2]4+ (100)
(Fig. 17) show good cytotoxicities (IC50 6 and 4 mM,
respectively).105
Hexanuclear arene rutheniumcomplexes that formhexacationic
cages have been synthesized using dbq bridges and tripodal
2,4,6-tris(pyridin-4-yl)1,3,5-triazine (tpt) linkers: the cation [{(h6-
p-MeC6H4Pri)Ru}6(N,N,N-tpt)2(O,O:O,O-dbq)3]6+ (101) forms
by self-assembly from tpt and the dinuclear precursor [(h6-p-
MeC6H4Pri)Ru]2(O,O:O,O-dbq)2Cl2 in the presence of silver tri-
ﬂate and crystallizes as the triﬂate salt. If the synthesis is done in the
presence of platinum or palladium bisacetylacetonate, the planar
complex is encapsulated in the hexaruthenium cage to give the
carciplex systems [(acac)2MÃ{(h6-p-MeC6H4Pri)Ru}6(N,N,N-
tpt)2(O,O:O,O-dbq)3]6+ (M = Pt 102, M = Pd 103), for which
we coined the term “complex-in-a-complex” systems (Fig. 18),
accessible as triﬂate salts.106
All these systems are active against human ovarian (A2780)
cancer cells: The empty hexaruthenium cage 101 has already
an IC50 value of 23 mM, by using the platinum-containing cage
102 the cytotoxicity doubles (IC50 12 mM), and by using the
palladium-containing cage 103 the activity goes up by a factor
of twenty (IC50 1 mM), while free Pt(acac)2 and Pd(acac)2 are
completely inactive due to their insolubility in water. The working
hypothesis of a “Trojan Horse” strategy to deliver a hydrophobic
13
Fig. 19 Dentritic arene ruthenium complex cations of 1st and 2nd generation.
metal-containing host to a cancer cell by a water-soluble cage
molecule produces a synergistic effect, because the cage molecule
itself is cytotoxic, and the cytotoxicity is increased by the release
of the encapsulated active complex.106
The tetra- and octanuclear arene ruthenium complexes [(h6-
p-MeC6H4Pri)RuCl2]4(N:N:N:N-dendG1) (104), [(h6-C6Me6)-
RuCl2]4(N:N:N:N-dendG1) (105), [(h6-p-MeC6H4Pri)RuCl2]8-
(N:N:N:N:N:N:N:N-dendG2) (106) and [(h6-p-C6Me6)RuCl2]8-
(N:N:N:N:N:N:N:N-dendG2) (107), containing the ﬁrst or sec-
ond generation of a diaminobutane-based dendrimer with four
(dendG1) or eight (dendG2) iminopyridyl dendrons (Fig. 19),
were found to be moderately cytotoxic (IC50 20–43 mM) without,
however, a pronounced size effect.107
Outlook
Water-soluble arene ruthenium complexes are an emerging class
of molecules for the design of anticancer drugs, not only because
of the supposed afﬁnity of cancer cells for the iron homologue
ruthenium and because of the low systemic toxicity of many ruthe-
nium compounds, but also because arene ruthenium complexes
combine lipophilicity and hydrophilicity, which is very important
for their transport in biological media. Since not only additive
but synergistic effects have been observed with multinuclear
arene ruthenium complexes, and since coupling with molecules of
distinct biological function allows targeted chemotherapy, cationic
arene ruthenium cagemolecules containing other drugs seem to be
one of the promising strategies for the development of synergistic
anticancer drugs.
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